Revvity

Methodology

Revvity's diagnostics and life sciences tools serve research and clinical labs with recurring revenue from consumables and service contracts. The calculation works reasonably well when normalizing for biopharma R&D spending cycles and clinical diagnostics trends. Recurring revenue from installed instrument base provides earnings predictability.

Methodology

Revvity typically trades at moderate PEG ratios reflecting life sciences tools market maturity offset by diagnostics growth and emerging market opportunities. The metric should account for biopharma funding cycles and COVID testing normalization. Compare to other life sciences tools companies like Thermo Fisher while considering Revvity's scale and portfolio breadth.

Methodology

Revvity offers a modest dividend as management balances capital returns with R&D investments and strategic acquisitions in diagnostics. The small dividend adds some value though capital appreciation matters more. For life sciences tools companies, organic growth and acquisition execution matter more than current yield.